StageZero Life Sciences Ltd. (SZLSF)
USD 0.02
(533.33%)
USD 0.02
(533.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -10.27 Million USD | 2.1% |
| 2021 | -7.62 Million USD | -118.84% |
| 2020 | -6.25 Million USD | 27.67% |
| 2019 | -2.43 Million USD | -19.05% |
| 2018 | -2.66 Million USD | -13.95% |
| 2017 | -2.25 Million USD | 23.76% |
| 2016 | -4.65 Million USD | -63.56% |
| 2015 | -5.99 Million USD | -37.52% |
| 2014 | -6.92 Million USD | 62.34% |
| 2013 | -5.49 Million USD | -40.18% |
| 2012 | -3.91 Million USD | -22.68% |
| 2011 | -3.2 Million USD | 7.65% |
| 2010 | -3.29 Million USD | 17.83% |
| 2009 | -4.2 Million USD | 58.36% |
| 2008 | -9.58 Million USD | -6.97% |
| 2007 | -9.45 Million USD | -30.22% |
| 2006 | -7.26 Million USD | -243.99% |
| 2005 | -2.11 Million USD | 48.44% |
| 2004 | -4.09 Million USD | -8660.79% |
| 2003 | -46.72 Thousand USD | 93.95% |
| 2002 | -772.83 Thousand USD | 30.89% |
| 2001 | -1.11 Million USD | -353.25% |
| 2000 | -1.11 Million USD | -717.61% |
| 1999 | -246.73 Thousand USD | 687.31% |
| 1998 | -6802.08 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -296.57 Thousand USD | 0.0% |
| 2024 Q2 | -552.98 Thousand USD | -69.67% |
| 2023 Q3 | -722.63 Thousand USD | 5.06% |
| 2023 Q1 | -1.32 Million USD | 20.74% |
| 2023 Q2 | -761.17 Thousand USD | 42.42% |
| 2022 Q1 | -2.54 Million USD | 12.02% |
| 2022 Q3 | -1.28 Million USD | 33.55% |
| 2022 Q2 | -1.92 Million USD | 24.16% |
| 2022 FY | - USD | 2.1% |
| 2022 Q4 | -1.66 Million USD | -30.17% |
| 2021 Q1 | -1.64 Million USD | -138.78% |
| 2021 Q3 | -2.27 Million USD | 0.35% |
| 2021 Q4 | -2.88 Million USD | -26.83% |
| 2021 Q2 | -2.28 Million USD | -39.27% |
| 2021 FY | - USD | -118.84% |
| 2020 Q3 | -518.23 Thousand USD | 53.74% |
| 2020 Q4 | -687.57 Thousand USD | -32.68% |
| 2020 FY | - USD | 27.67% |
| 2020 Q1 | -835.62 Thousand USD | 26.29% |
| 2020 Q2 | -1.12 Million USD | -34.06% |
| 2019 FY | - USD | -19.05% |
| 2019 Q1 | -1.16 Million USD | -1143.85% |
| 2019 Q4 | -1.13 Million USD | 5.36% |
| 2019 Q3 | -1.19 Million USD | 9.04% |
| 2019 Q2 | -1.31 Million USD | -12.87% |
| 2018 Q4 | -93.79 Thousand USD | 91.19% |
| 2018 FY | - USD | -13.95% |
| 2018 Q1 | -1.04 Million USD | -519.52% |
| 2018 Q2 | -1.66 Million USD | -59.06% |
| 2018 Q3 | -1.06 Million USD | 36.1% |
| 2017 Q1 | -1.2 Million USD | -68.96% |
| 2017 FY | - USD | 23.76% |
| 2017 Q3 | -1.06 Million USD | 26.28% |
| 2017 Q4 | 249.81 Thousand USD | 123.55% |
| 2017 Q2 | -1.43 Million USD | -19.44% |
| 2016 FY | - USD | -63.56% |
| 2016 Q1 | -1.15 Million USD | -57.79% |
| 2016 Q4 | -712.99 Thousand USD | 55.74% |
| 2016 Q3 | -1.61 Million USD | -36.48% |
| 2016 Q2 | -1.18 Million USD | -2.51% |
| 2015 Q1 | -126.31 Thousand USD | -104.59% |
| 2015 Q2 | -394.42 Thousand USD | -212.26% |
| 2015 Q3 | -1.59 Million USD | -303.54% |
| 2015 FY | - USD | -37.52% |
| 2015 Q4 | -729.64 Thousand USD | 54.16% |
| 2014 FY | - USD | 62.34% |
| 2014 Q4 | 2.75 Million USD | 444.47% |
| 2014 Q3 | -798.71 Thousand USD | 2.38% |
| 2014 Q2 | -818.15 Thousand USD | 49.24% |
| 2014 Q1 | -1.61 Million USD | -48.89% |
| 2013 FY | - USD | -40.18% |
| 2013 Q4 | -1.08 Million USD | 35.26% |
| 2013 Q3 | -1.67 Million USD | -9.88% |
| 2013 Q2 | -1.52 Million USD | -26.25% |
| 2013 Q1 | -1.2 Million USD | -57.16% |
| 2012 Q2 | -973.25 Thousand USD | 0.87% |
| 2012 Q4 | -766.98 Thousand USD | 33.47% |
| 2012 Q1 | -981.81 Thousand USD | -0.66% |
| 2012 Q3 | -1.15 Million USD | -18.44% |
| 2012 FY | - USD | -22.68% |
| 2011 FY | - USD | 7.65% |
| 2011 Q1 | -842.27 Thousand USD | -38.63% |
| 2011 Q2 | -801.3 Thousand USD | 4.86% |
| 2011 Q3 | -2.94 Million USD | -268.04% |
| 2011 Q4 | -975.35 Thousand USD | 66.93% |
| 2010 Q3 | -753.75 Thousand USD | 21.2% |
| 2010 Q4 | -607.58 Thousand USD | 19.39% |
| 2010 Q2 | -956.58 Thousand USD | 15.33% |
| 2010 Q1 | -1.12 Million USD | -557.08% |
| 2010 FY | - USD | 17.83% |
| 2009 Q4 | 247.17 Thousand USD | 123.81% |
| 2009 Q2 | -1.21 Million USD | 8.24% |
| 2009 Q1 | -1.32 Million USD | -36.83% |
| 2009 Q3 | -1.03 Million USD | 14.49% |
| 2009 FY | - USD | 58.36% |
| 2008 Q4 | -967.04 Thousand USD | 71.6% |
| 2008 Q1 | -2.33 Million USD | 56.08% |
| 2008 Q2 | -3.63 Million USD | -55.78% |
| 2008 Q3 | -3.4 Million USD | 6.31% |
| 2008 FY | - USD | -6.97% |
| 2007 FY | - USD | -30.22% |
| 2007 Q1 | -1.43 Million USD | 24.73% |
| 2007 Q2 | -1.79 Million USD | -25.0% |
| 2007 Q3 | -2.56 Million USD | -42.95% |
| 2007 Q4 | -5.31 Million USD | -107.03% |
| 2006 Q4 | -1.9 Million USD | 0.66% |
| 2006 Q3 | -1.92 Million USD | -19.27% |
| 2006 Q2 | -1.61 Million USD | 7.61% |
| 2006 Q1 | -1.74 Million USD | -600.03% |
| 2006 FY | - USD | -243.99% |
| 2005 Q2 | -467.52 Thousand USD | 42.06% |
| 2005 Q3 | -1.11 Million USD | -137.9% |
| 2005 FY | - USD | 48.44% |
| 2005 Q4 | 348.51 Thousand USD | 131.33% |
| 2005 Q1 | -806.9 Thousand USD | -107.61% |
| 2004 FY | - USD | -8660.79% |
| 2004 Q2 | -1.32 Million USD | -38.25% |
| 2004 Q4 | -388.65 Thousand USD | 69.81% |
| 2004 Q1 | -961.41 Thousand USD | -31813.53% |
| 2004 Q3 | -1.28 Million USD | 3.15% |
| 2003 Q2 | -354.06 Thousand USD | -149.73% |
| 2003 Q3 | -468.19 Thousand USD | -32.23% |
| 2003 Q4 | 3031.57 USD | 100.65% |
| 2003 Q1 | 711.97 Thousand USD | 365.74% |
| 2003 FY | - USD | 93.95% |
| 2002 FY | - USD | 30.89% |
| 2002 Q4 | -267.92 Thousand USD | 41.39% |
| 2002 Q1 | -439.22 Thousand USD | -54.05% |
| 2002 Q2 | -797.86 Thousand USD | -81.65% |
| 2002 Q3 | -457.1 Thousand USD | 42.71% |
| 2001 Q1 | -396.94 Thousand USD | -65.69% |
| 2001 FY | - USD | -353.25% |
| 2001 Q4 | -285.11 Thousand USD | -74.86% |
| 2001 Q3 | -163.05 Thousand USD | 35.15% |
| 2001 Q2 | -251.41 Thousand USD | 36.66% |
| 2000 Q4 | -239.56 Thousand USD | 0.4% |
| 2000 Q3 | -240.54 Thousand USD | 0.0% |
| 2000 Q1 | -8106.49 USD | -113.13% |
| 2000 FY | - USD | -717.61% |
| 1999 FY | - USD | 687.31% |
| 1999 Q4 | 61.72 Thousand USD | 1422.72% |
| 1999 Q1 | -7332.45 USD | 0.0% |
| 1999 Q3 | -4666.29 USD | 52.56% |
| 1999 Q2 | -9836.62 USD | -34.15% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -783.073% |
| Arrayit Corporation | -3.07 Million USD | -233.718% |
| Atlantic International Corp. | -5.38 Million USD | -90.556% |
| Biocept, Inc. | -30.24 Million USD | 66.039% |
| Bioqual, Inc. | 3.03 Million USD | 438.698% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -1256.018% |
| DermTech, Inc. | -97.89 Million USD | 89.509% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.352% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 49.264% |
| iMD Companies, Inc. | -154.65 Thousand USD | -6540.506% |
| IDenta Corp. | 71.58 Thousand USD | 14446.376% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 367.661% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 26644.689% |
| InVitro International | 6680.00 USD | 153844.611% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | -88.928% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -84539.36% |
| Medical Imaging Corp. | -896.74 Thousand USD | -1045.273% |
| NovelStem International Corp. | -3.78 Million USD | -171.281% |
| Optigenex Inc. | -1.18 Million USD | -765.419% |
| PharmChem, Inc. | 1.05 Million USD | 1074.572% |
| Proteome Sciences plc | -1.13 Million USD | -803.266% |
| Response Genetics, Inc | -19.66 Million USD | 47.777% |
| Rennova Health, Inc. | -234.81 Thousand USD | -4273.715% |
| RushNet, Inc. | -614.85 Thousand USD | -1570.343% |
| ScreenPro Security Inc. | -3.43 Million USD | -198.995% |
| Stella Diagnostics Inc. | -5.7 Million USD | -79.943% |
| Todos Medical Ltd. | -9.39 Million USD | -9.327% |